Head-to-head · free
Novartis vs Viking Therapeutics
A vs VKTX — return on capital, cash generation, margins and balance sheet side by side.
A
3 / 4
measures where A leads
VKTX
1 / 4
measures where VKTX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | A · FY2025 | VKTX · FY2025 |
|---|---|---|
| Revenue | $6.9B | $0 |
| Net income | $1.3B | (359.6M) |
| Revenue growth (yearly, multi-year) | 2.4% | — |
| Free cash flow | $1.2B | — |
| Free cash flow margin | 16.6% | — |
| Net cash / (debt) | — | — |
| ROIC | 13.9% | — |
| Return on equity | 20.6% | -47.3% |
| Gross margin | 52.4% | — |
| Operating margin | 21.3% | — |
| Net debt / EBITDA | 0.89x | 0.42x |
Figures are as reported by each company; latest fiscal year shown.
Where Novartis's cash went (FY2025)
- Capital spending
- $407.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Viking Therapeutics's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free